

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

RESUMPTION OF TRADING

The Company and all members of the board of Directors hereby confirm the truthfulness, accuracy and completeness of the contents of this announcement and jointly and severally accept full responsibility for any false representation, misleading statement or material omission herein contained.

Guangzhou Pharmaceutical Company Limited (**the “Company”**) had been involved in a proposed possible event (**the “Event”**), which is considered to be price sensitive, and had applied for a suspension in the dealing of the shares of the Company on 24 August 2009 in order to prevent the leakage of information regarding the Event. After studies, the Company decides not to pursue with the Event in the near future, and it will not plan for the Event within the next three months.

Application has been made to The Stock Exchange of Hong Kong Limited (“Stock Exchange”) for the resumption of trading in the Shares of the Company on the Stock Exchange from 9:30 a.m. on 25 August 2009.

By Order of the Board
Guangzhou Pharmaceutical Company Limited
Yang Rongming
Chairman

Guangzhou, the PRC, 24 August 2009

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Shi Shaobin and Mr. Feng Zansheng as Executive Directors, and Mr. Wong Hin Wing, Mr. Liu Jinxiang, Mr. Li Shanmin and Mr. Zhang Yonghua as Independent Non-executive Directors.